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Abstract
Background Death with a functioning kidney graft
(DWFG) is now a major cause of graft loss after renal
transplantation, occurring in up to 40% of cases. Its
occurrence provides insight into the medical care of
subjects with a functioning kidney transplant. In this
study, we used the time to DWFG as an endpoint, to
test whether improved medical care has contributed
to better kidney transplant outcomes.
Methods We used single-center data from the
Milwaukee Regional Medical Center and Froedtert
Hospital, on kidney-only transplants from 1969
through 2005. A total of 3,157 kidney transplants
were done at our center during this time. There were
714 deaths with functioning kidney. We also
recorded the major causes of DWFG over the time
period from 1969 through 2005 divided into 3
epochs. The data were analyzed as a serial collection
of yearly obituaries.
Results The time to DWFG has increased to
10 years despite a 20-year increase in the mean age
of transplant recipients over the same time period.
Conclusions Betterpre-transplantevaluation,improved
treatments for hypertension and hyperlipidemia,
improvedmanagementofacutemyocardialinfarction,
superior immunosuppressive protocols and better
prophylaxis and treatment of infectious diseases have
all likely contributed to this trend.
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Introduction
Kidney transplant survival has improved in recent
years [1, 2]. This improvement is often credited to
better immunosuppressive protocols, with reduced
rejection rates and also lesser medication toxicity. But
general medical care may also affect kidney transplant
patientsurvival.Thisaspectofpost-transplantcarehas
not been well quantiﬁed, and its impact may be
ignored if graft survival rates are censored for death
with functioning graft. Yet, death with a functioning
kidney graft (DWFG) is a major cause of graft loss
after renal transplantation, occurring in 10–40% of
transplants [3–6]. Because it does not consider loss of
the kidney transplant and resumption of dialysis, time
to DWFG does not incorporate graft loss due to
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provide insight into post-transplant medical care. In
this study, we used the time to DWFG as an endpoint,
to test whether improved medical care has contributed
to better kidney transplant outcomes.
Methods
We used single-center data from the Milwaukee
Regional Medical Center and Froedtert Hospital, on
kidney-only transplants from 1969 through 2005. A
total of 3,157 kidney transplants were done at our
center during this time. The cause of ESRD was
ascertained at the time of ﬁrst encounter or listing and
from the Form CMS 2728. There were 714 deaths
with functioning kidney, 564 in subjects with
deceased donor transplants. We also recorded the
major causes of DWFG over the time period from
1969 through 2005 divided into 3 epochs. The cause
of death was ascertained from the hospital records
and death certiﬁcate information. The data were
analyzed as a serial collection of yearly obituaries.
That is, the median age at time of death was
calculated for all subjects dying in a particular year,
and those median ages were graphed as a function of
year of death, rather than year of transplant. This
method is realistic because it corresponds to day-to-
day experience. It also eliminates confounding by
less time of follow-up in more recent years. Finally,
we obtained the general population mortality data
from the State of Wisconsin for the years included in
this study. The study is fully approved by the Human
Research Review Committee of the Medical College
of Wisconsin.
Results
In the time period from 1969 to 2005, there were 714
deaths with functioning kidney, 564 in subjects with
deceased donor transplants. Of these 564 subjects,
65% were men and 35% were women recipients of
deceased donor kidney transplant. Of the subjects
with DWFG who had living donor transplants, 64%
were men and 36% were women. There has been an
increase in median time to DWFG from about one
year in 1969 to 10 years in year 2005 (Fig. 1). During
this same time, there was a 20-year increase in
median age of kidney transplant recipients at time of
transplant (Fig. 2). In addition, in epoch 1, (1969–
1980), 5% of the kidney disease was caused by
diabetes whereas in epoch 2 (1981–1992) and epoch
3 (1993–2005), respectively, 41% and 47% of the
kidney disease was secondary to diabetes. For epochs
1, 2 and 3, hypertension was the underlying cause of
kidney disease in 2%, 11% and 10% respectively.
The increase in time to DWFG is 10 years over the
same total time period. A separate analysis of deaths
by epoch showed changes with time, notably a
reduced proportion of death caused by infection
(Fig. 3).
Fig. 1 Showing increasing median time to death with
functioning graft (DWFG) from years 1969 through 2005
Fig. 2 Showing an increasing median age at time of transplant
with the each year of transplant
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These data show an increase in median time to death
with functioning graft over the last 30 years despite
the aging population of transplant recipients, and in
the face of a substantial increase in the numbers of
patients with diabetes as the cause of their kidney
failure. Over the same time period as this study, the
median age at death in general population of the State
of Wisconsin for the same period has increased from
age 73 to age 80 [7]. It is likely that the subjects of
our study were helped by the medical care advances
over this time, in a way that is parallel to the general
population. A recent review of transplant outcomes in
the elderly population by Saxena et al. have also
highlighted better survival in elderly transplant
recipients attributable to multiple factors [8].
Ojo et al. also showed improvement in survival of
subjects with a functioning kidney transplant [6]. But
this analysis was limited to the time period 1988 to
1997. Our cohort includes subjects before that time
periodandafterit.Inaddition,whileOjoetal.reported
a decline in DWFG in terms of risk reduction, our
analysis additionally provides the immediately useful
practical information of the actual number of years of
patient survival with a functioning transplant.
Better pre-transplant evaluation, pre- and post-
transplant cardiovascular risk factor modiﬁcation and
treatment, and better post-transplant care of infec-
tions are likely contributors to the increasing time to
death with functioning graft.
Recent reports show a signiﬁcant reduction in
coronary heart disease mortality in the general
population in the year 2000 when compared to the
year 1980 [9]. This effect is attributable equally to
reduction in risk factors and use of evidence-based
medical therapies. In the case of kidney transplant
patients, the role of hyperlipidemia and other risk
factors is similar to that of the general population
[10]. There are additional risk factors in subjects with
kidney transplants, such as the effect of reduced
kidney function, which are not present in the general
population. Nonetheless, death from IHD (Ischemic
heart disease) in people with a kidney transplant is
signiﬁcantly associated with traditional risk factors of
hypertension, increasing age, lower HDL, diabetes
mellitus (DM), hypercholesterolemia, baseline con-
gestive heart failure (CHF) and cardiovascular dis-
ease (CVD) history [10]. Ivens et al. concluded that
the high incidence of CVD following renal transplant
was mainly due to increased prevalence and accu-
mulation of classic risk factors before and following
transplant [11]. Since the cardiovascular disease in
kidney transplant patients shares the same risk factors
for cardiovascular disease as in general population,
their modiﬁcation, as observed in the general popu-
lation, is expected to improve the cardiovascular
disease outcomes [12].
Indeed, the European ALERT extension study
demonstrated a signiﬁcant reduction in risk of cardiac
death and non-fatal MI in renal transplant patients
with moderate elevation in cholesterol treated with
ﬂuvastatin when compared to those treated with
placebo [13]. An American study reported a 24%
reduction in mortality in patients treated with statins
when compared to placebo [14]. More recently, a
study looking at a cohort of 2041 ﬁrst-time renal
transplant recipients from 1990 to 2003 reported
improved survival in patients on statins when com-
pared to not being on statins (HR (adj) 0.64, 95% CI
0.48–0.86) [15]. In conﬁrmation of these reports,
the USRDS in its 2007 annual data report shows
signiﬁcant improvement in 1- and 5-year survival of
kidney transplant patients after a diagnosis of heart
disease [16]. In neither the USRDS data nor in the
present report can we conﬁrm the role of statins
because we have no stored data on their use. It is
likely, however, that use of statins has increased
steadily since 1985, which is at or about the time
when time to death with functioning transplant began
to increase (Fig. 1). Hypertension control appears to
play a signiﬁcant role in better kidney transplant
survival. A cohort analysis from the Collaborative
Fig. 3 Depicting changing trends in cause of death kidney
transplant recipients in each of the three epochs (1969–1980;
1981–1992; 1993–2005)
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survival and lesser cardiovascular deaths with control
of the systolic blood pressure to less than 140 mm Hg
[17]. Over the past three decades, control of the blood
pressure has become more effective, and with less
side effects. Use of angiotensin-converting enzyme
inhibitors has increased steadily since the mid-1980s,
coinciding with the upswing in time to death with
functioning graft (Fig. 1) This aspect of cardiovas-
cular risk reduction is likely to have played an
important role in improving kidney transplant patient
survival in our cohort. But we cannot conﬁrm this,
because we have no stored data on blood pressures of
type of antihypertensive use in these patients.
Treatment for disease has also improved. In the
general population, there has been a 30% reduction in
one-year mortality after myocardial infarction in
1992–1994 when compared to 1981–1983, which is
attributed to evidence-based therapies [18]. Better
cardiac interventions over the years have also helped
in subjects with functioning kidney transplants.
Herzog and colleagues retrospectively examined
outcomes of renal transplant recipients hospitalized
during 1977–1996 for a ﬁrst acute myocardial
infarction (AMI) and reported markedly improved
long-term survival of renal transplant recipients after
AMI in the modern treatment era [19].
Acute rejection episodes have been identiﬁed as
risk factors for development of cardiovascular disease
namely ischemic heart disease and cerebral vascular
disease [13]. Use of better immunosuppression pro-
tocols over the past three decades has thus contrib-
uted indirectly to decreased prevalence of CVD
mortality by reducing rejection rates. A recent study
from Vienna looked at 1823 ﬁrst kidney transplants
from 1990 to 2003. They found signiﬁcantly better
patient survival for patients who received Calcineurin
inhibitor containing maintenance immunosuppression
when compared to those without it (0.41, 95% CI
0.30–0.57) [20].
Besides the decreased cardiovascular mortality, a
decrease in infection-related post-transplant mortality
has also contributed to better patient survival [5].
Better infection control practices, better antibiotics
and anti-virals, and reduced overall immunosuppres-
sion are all likely factors in the decrease in infection-
related mortality in transplant patients. Speciﬁcally,
valaciclovir prophylaxis has been reported to improve
survival in renal transplant patients who are at high
risk for developing CMV disease [21]. A recent
Cochrane database systematic review conﬁrmed this
by examining 34 studies with 3,850 participants. This
meta-analysis study concluded that prophylaxis
with antiviral medications reduces CMV disease and
CMV-related mortality in solid organ transplants [22].
Prophylaxis with acyclovir, ganciclovir or valacylco-
vir has also been reported to reduce the risks of
diseasesassociatedwithherpessimplex,herpeszoster,
bacterial and protozoal infections [23]. Universal
immunization of a transplant recipient has also likely
contributed to decreased infectious mortality. Better
pre-transplant evaluation of the recipient in terms of
cancer screening, cardiovascular risk factors identiﬁ-
cation and their modiﬁcation could contribute to this
trend of increased survival to DWFG event. However,
after transplantation, in subjects with functioning
kidney transplants, routine testing for cancer in all
likelihood does not reduce overall mortality and thus
cannot explain the impressive gains in patient survival
to time of DWFG that we have shown [24, 25].
Our 10-year median time to DWFG contrasts with
data from USRDS that report a median time to
DWFG of 6.5 years in the year 2005. Ours is a single-
center data, and its values can deviate from the
population mean, in this case USRDS data, within 2
standard deviations of the population mean. Another
possible explanation is the differential age distribu-
tion of our data and the USRDS data such that a
relatively younger segment of population was being
transplanted during each year when compared to our
corresponding single-center experience.
This is consistent with the report of Ojo et al., who
found that increasing age at transplant was signiﬁ-
cantly associated with DWFG [6]. Also, younger
patients are more likely to survive to graft failure and
resume dialysis.
A major limitation of our study is its retrospective
nature. We see an increase in time to death with
functioning graft (DWFG) in our data, and we have
cited publisheddatatoattributeittoimprovedmedical
practices, the foremost of which being modiﬁcation of
cardiac risk factors and management of cardiac and
infectious disease. However, because of the retrospec-
tivenatureofourstudy,whichspannedovermorethan
three decades, some of the data on such practices were
not systematically collected and stored. In addition, no
data were collected and stored on non-traditional risk
factors as many of them were identiﬁed as novel CV
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althoughweseebeneﬁtintermsofimprovedoutcomes
at our center, the current study is somewhat limited in
attributing those beneﬁts directly to our changing and
improved practices. Nevertheless, the medical prac-
ticesthatledtotheimprovementintimetoDWFGand
their approximate time of introduction into clinical
practicearesimilartotheadoptionofthosepracticesat
out center.
In conclusion, patient survival with a functioning
kidney transplant has increased. This points to
improvements in medical care as important factors
in better kidney transplant outcomes.
Factors that may play a role in this improvement
include: better pre-transplant evaluation, better treat-
ment for traditional cardiovascular risk factors such
as hypertension and hyperlipidemia, improved man-
agement of myocardial infarction, superior immuno-
suppressant protocols and better prophylaxis and
treatment of infections. The advances in medical care
that have helped the general population to live longer
are likely to have also improved the survival of
kidney transplant patients.
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